Effects of Montelukast sodium combined with Salmeterol/Fluticasone in treatment of patients with asthma-chronic obstructive pulmonary disease overlap syndrome
Objective:To observe effects of Montelukast sodium combined with Salmeterol/Fluticasone in treatment of patients with asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS).Methods:A prospective study was conducted on 94 patients with ACOS admitted to the hospital from May 2020 to May 2023.According to the random number table method,they were divided into control group and observation group,47 cases in each group.Both groups were given routine treatment.On this basis,the control group was treated with Salmeterol/Fluticasone,while the observation group was treated with Montelukast sodium on the basis of that of the control group.The clinical efficacy,the clinical symptoms[asthma control test(ACT),chronic obstructive pulmonary disease assessment test(CAT),dyspnea classification(MRC)]scores,the lung function indexes[forced vital capacity(FVC),forced expiratory volume in one second(FEV1)/FVC,maximum expiratory flow(PEF)]levels,the inflammatory factors[interleukin-18(IL-18),interferon-γ(INF-γ),matrix metalloproteinase inhibitor-1(TIMP-1),matrix metalloproteinase-9(MMP-9)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 89.36%(42/47),which was higher than 70.21%(33/47)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the MRC and CAT scores of the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the ACT scores of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;and the differences were statistically significant(P<0.05).The levels of FVC,FEV1/FVC and PEF in the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of IL-18,INF-γ,TIMP-1 and MMP-9 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Montelukast sodium combined with Salmeterol/Fluticasone in the treatment of the ACOS patients can improve the clinical efficacy,reduce the clinical symptoms,inhibit the airway inflammation reactions,and improve the lung function.Moreover,it is superior to single Salmeterol/Fluticasone treatment.
Asthma-chronic obstructive pulmonary disease overlap syndromeSalmeterolMontelukast sodiumLung function
万方数据
维普
